sunitinib + oxaliplatin + capecitabine

**Sunitinib + oxaliplatin + capecitabine** is an investigational combination regimen studied primarily for advanced gastric cancer. It combines: - **Sunitinib**, a small-molecule multi-targeted receptor tyrosine kinase inhibitor that blocks cellular signaling by targeting several kinases, including vascular endothelial growth factor receptor (VEGF-R), platelet-derived growth factor receptor (PDGF-R), KIT, FLT3, RET, and CSF-1R[9]. This leads to antiangiogenic and direct antitumor activity. - **Oxaliplatin**, a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, thereby causing cell death[1][3][7]. - **Capecitabine**, an oral prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, impairing DNA synthesis and leading to cell death in rapidly dividing cells[1][3][7]. Used together, the regimen exhibits additive or synergistic antitumor and antiangiogenic effects. The primary indication studied is advanced gastric cancer, with ongoing investigation for other solid tumors[4][5][8].

Brand names

Sutent (for sunitinib)Xeloda (for capecitabine)sunitinib + oxaliplatin + capecitabine

Other names

XELOX + sunitinibsunitinib/XELOXsunitinib plus oxaliplatin plus capecitabine